Citi raised the firm’s price target on Integra LifeSciences (IART) to $11 from $9 and keeps a Sell rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra Lifesciences Earnings Call Highlights Mixed Recovery
- Morning Movers: PayPal, Shopify drop following quarterly earnings reports
- Integra LifeSciences Names Stuart Essig President and CEO
- Integra LifeSciences raises FY26 adjusted EPS to $2.40-$2.50 from $2.30-$2.40
- Integra LifeSciences says Stuart Essig appointed as next CEO